A correção cirúrgica de algumas cardiopatias congênitas complexas envolve a reconstrução da via de saída do ventrículo direito com a interposição de homoenxertos, biopróteses, enxertos de jugular bovina ou outros condutos valvulados entre o ventrículo direito e o tronco da artéria pulmonar. Apesar de essas cirurgias poderem ser realizadas com baixa mortalidade, a vida útil das válvulas ou dos condutos implantados é normalmente pequena (< 10 anos), seja por degeneração e/ou calcificação. Graus variáveis de estenose pulmonar na maioria das vezes associada a insuficiência pulmonar são consequências da degeneração dos condutos. Em 2000, Bonhoeffer et al. foram os primeiros a relatar o implante transcateter de bioprótese valvular pulmonar (ITVP) com um dispositivo que posteriormente foi denominado de válvula Melody® (Medtronic, Minneapolis, Estados Unidos). A técnica foi inicialmente desenvolvida para limitar a necessidade de múltiplos procedimentos cirúrgicos, substituindo, em última análise, uma nova troca cirúrgica valvular. Estudos subsequentes na Europa e Estados Unidos atestaram para a segurança e eficácia dessa técnica em um número maior de pacientes. Como a Agência Nacional de Vigilância Sanitária (Anvisa) concedeu a aprovação para o uso clínico da válvula biológica pulmonar transcateter Melody® em fevereiro de 2013, consideramos necessária e oportuna a avaliação judiciosa da utilização dessa nova tecnologia antes que ela fosse aplicada em larga escala em nosso país. O objetivo deste estudo foi realizar uma revisão sistemática da literatura sobre o ITVP em pacientes com disfunções de homoenxertos, condutos valvulados e biopróteses implantados cirurgicamente na via de saída do ventrículo direito.

Surgical repair of some complex congenital heart diseases involves reconstruction of the right ventricular outflow tract using homografts, bioprostheses, bovine jugular grafts or other valved conduits between the right ventricle and the main pulmonary artery. Although these surgical procedures may be performed with low mortality rates, the life span of these implanted valves or conduits is usually short (< 10 years) due to either degeneration and/or calcification. Variable degrees of pulmonary stenosis, often associated with pulmonary insufficiency, are consequences of conduit degeneration. In 2000, Bonhoeffer et al. were the first to report the transcatheter pulmonary valve implantation (TPVI) of a bioprosthetic pulmonary valve later named Melody® valve (Medtronic, Minneapolis, USA). The technique was initially developed to limit the need for multiple surgical procedures, and, ultimately, to work as a surrogate of a new surgical valve replacement. Subsequent clinical studies in Europe and the United States confirmed the safety and efficacy of this technique in a larger number of patients. Since the National Sanitary Surveillance Agency (Agência Nacional de Vigilância Sanitária - Anvisa) granted approval for clinical use of the Melody® transcatheter pulmonary biological valve in February 2103, we deemed that a judicious assessment of this new technology was timely and necessary before the widespread use in our country. The objective of this study was to perform a systematic literature review on the use of TPVI in patients with dysfunctional homografts, valved conduits and bioprostheses implanted surgically in the right ventricular outflow tract.

INTRODUÇÃO: Uma nova geração de próteses Amplatzer com menor perfil e maior flexibilidade foi desenvolvida recentemente para o tratamento percutâneo da persistência do canal arterial (PCA). Neste artigo é relatado o uso desse novo dispositivo, Amplatzer Duct Occludder II TM (ADO II), para o tratamento tanto de PCA como de outros defeitos congênitos e estruturais, avaliando sua eficácia e segurança. MÉTODOS: Estudo longitudinal observacional de uma coorte de pacientes portadores de cardiopatias congênitas e estruturais tratados com ADO II entre outubro de 2009 e agosto de 2011. Pacientes com menos de 5 kg e canais > 5,5 mm e/ou do tipo B foram excluídos do estudo. A prótese foi implantada por vias anterógrada ou retrógrada. A cintura foi cerca de 2 mm maior que o defeito e o comprimento da prótese foi de 4 mm para lesões mais curtas (até 6-8 mm). RESULTADOS: Foram incluídos no estudo 28 pacientes, com mediana de idade e de peso de 2 anos e 11,7 kg, respectivamente, dos quais 23 eram portadores de PCA com diâmetro mínimo de 2,3 + 0,8 mm. Os demais apresentavam comunicação interventricular muscular (1), fístula arteriovenosa pulmonar (1), aneurisma roto do seio de Valsalva (1), e coração univentricular em pós-operatório recente de cavopulmonar bidirecional com fluxo anterógrado pulmonar residual (2). Em todos os pacientes a prótese foi implantada com sucesso, com exceção de um lactente de 8 kg com canal arterial de 2,8 mm de diâmetro, de ampola rasa e de trajeto longo, tortuoso e oblíquo. Houve oclusão total dos defeitos em todos os pacientes. Um paciente portador de coração univentricular e isomerismo direito faleceu em decorrência de complicações não associadas ao procedimento. CONCLUSÕES: A prótese ADO II mostrou-se versátil, segura e eficaz no tratamento percutâneo de lactentes, crianças e adultos selecionados portadores de PCA e outras cardiopatias congênitas e estruturais. Sua aplicação pode ter limitações em algumas configurações anatômicas de PCA em lactentes menores.

BACKGROUND: A new generation of Amplatzer devices with lower profile and greater flexibility has been recently developed for percutaneous occlusion of the patent ductus arteriosus (PDA). In this paper, the use of this new device, the Amplatzer Duct Occludder II TM (ADO II) for percutaneous closure of the PDA as well as for the treatment of other congenital and structural heart defects is reported, assessing its safety and efficacy. METHODS: Longitudinal and observational study of a cohort of patients with congenital and structural heart defects treated with ADO II between October 2009 and August 2011. Patients weighing less than 5 kg and PDAs > 5.5 mm and/or type B were excluded. The device was implanted using the antegrade or retrograde approach. The waist was 2 mm larger than the defect and the length of the prosthesis was 4 mm for shorter lesions (less than 6-8 mm). RESULTS: Twenty-eight patients with a median age and weight of 2 years and 11.7 kg, respectively, were included. Twenty-three had a PDA with a mean minimal diameter of 2.3 + 0.8 mm. The remainder had muscular ventricular septal defect (1), pulmonary arteriovenous fistula (1), ruptured aneurysm of the sinus of Valsalva (1), and univentricular heart in the early postoperative period of bidirectional cavopulmonary anastomosis with residual antegrade pulmonary flow (2). The device was successfully implanted in all patients, except for an infant weighing 8 kg with a long, tortuous and oblique PDA with a diameter of 2.8 mm and a shallow ampulla. There was total occlusion of the defects in all patients. One patient with univentricular heart and right isomerism died due to complications not related to the procedure. CONCLUSIONS: ADO II proved to be a flexible, safe and effective device for the percutaneous treatment of infants, children and selected adults with PDA and other congenital and structural heart defects. Its use may have limitations for some anatomical PDA configurations in smaller infants.

INTRODUÇÃO: A formação de trombos no apêndice atrial esquerdo (AAE) constitui a principal causa de fenômenos tromboembólicos em pacientes com fibrilação atrial (FA). A anticoagulação oral é considerada terapia de primeira linha na prevenção de tromboembolismo associado à FA. Apesar de comprovada eficácia, a terapia com anticoagulantes orais está associada a inúmeras limitações. A oclusão percutânea do AAE surgiu como uma nova estratégia para prevenção de acidentes vasculares cerebrais em pacientes com FA considerados de alto risco e não candidatos a tratamento com anticoagulantes. MÉTODOS: Relatamos a experiência inicial da oclusão percutânea do AAE utilizando o novo dispositivo AmplatzerTM Cardiac Plug (ACP - AGA Medical Corp., Golden Valley, Estados Unidos) em pacientes com FA e escore CHADS2 > 2, não elegíveis à terapêutica com anticoagulantes. Os procedimentos foram realizados sob anestesia geral e monitoração por ecocardiografia transesofágica tridimensional em tempo real. RESULTADOS: Três pacientes do sexo masculino, com média de idade de 79 anos e escores CHADS2 2, 3 e 5, foram submetidos a implante do dispositivo por via transeptal sem complicações, resultando em oclusão imediata do AAE e alta hospitalar após dois dias. No seguimento de 50 dias, todos os pacientes se apresentavam bem clinicamente e a ecocardiografia transtorácica confirmou oclusão total do AAE e ausência de complicações. CONCLUSÕES: A oclusão percutânea do AAE com ACP parece ser uma alternativa terapêutica atrativa na prevenção de eventos tromboembólicos em pacientes com FA e contraindicações ou limitações para anticoagulação oral.

BACKGROUND: Thrombus formation in the left atrial appendage (LAA) is the main cause of thromboembolic events in patients with non-valvular atrial fibrillation (AF). Oral anticoagulants are considered first-line therapy for stroke prevention in AF patients. Despite its proven efficacy, long-term oral anti-coagulation is associated to innumerous limitations. Percutaneous LAA closure has emerged as a new strategy for stroke prevention in high risk AF patients who are not candidates for long term oral anticoagulation therapy. METHODS: We report the initial experience with percutaneous occlusion of the LAA using the new AmplatzerTM Cardiac Plug (ACP - AGA Medical Corp., Golden Valley, USA) in patients with AF and CHADS2 score > 2 who were not eligible for anti-coagulation therapy. Procedures were carried out under general anesthesia and 3D transesophageal echocardiography monitoring in real time. RESULTS: Three male patients, mean age of 79 years and CHADS2 2, 3 and 5 scores had the device successfully implanted using a transeptal approach with no complications, resulting in immediate LAA occlusion and hospital discharge two days later. At the 50-day follow-up, all patients were clinically well with complete LAA occlusion and no complications at transthoracic echocardiography. CONCLUSIONS: Percutaneous LAA occlusion with the new ACP seems to be an attractive alternative to prevent thromboembolic events in patients with AF and contraindications or limitations for anticoagulation therapy.

INTRODUÇÃO: O tratamento percutâneo da comunicação interatrial tipo ostium secundum é a modalidade terapêutica de escolha em mais de 80% dos casos. Várias próteses encontram-se disponíveis para tal finalidade. Relatamos nossa experiência com a oclusão percutânea da comunicação interatrial com a prótese Figulla (Occlutech, Praga, República Tcheca), avaliando a segurança e a eficácia do método. MÉTODO: De abril de 2008 a março de 2010, foram realizados 25 procedimentos em dois centros de referência em 25 pacientes não-consecutivos (mediana de idade de 22 anos e de peso de 60 kg) sob anestesia geral e monitoração pela ecocardiografia transesofágica. Do total de comunicações interatriais, 23 eram únicas, com diâmetro médio de 17,5 ± 9,4 mm, e 2 eram múltiplas. Em um paciente foi necessário o uso de duas próteses em duas comunicações interatriais distantes. O diâmetro médio das próteses foi de 20,8 ± 7,4 mm, implantadas por bainhas longas de 9 F a 14 F pela veia femoral. RESULTADOS: Houve sucesso no implante em todos os casos. Em um caso houve embolização logo após a liberação, com resgate do dispositivo da aorta descendente seguido de novo implante. O seguimento médio foi de 12 meses e o índice de oclusão foi de 100%. Não houve complicações tardias. CONCLUSÃO: Nessa experiência inicial, a oclusão percutânea da comunicação interatrial com a prótese Figulla foi um procedimento de fácil execução, seguro e altamente eficaz.

BACKGROUND: Percutaneous treatment of ostium secundum atrial septal defect is the preferred therapy in over 80% of cases. Several devices are available for this purpose. We report our experience with the percutaneous closure of atrial septal defect with the Figulla device (Occlutech, Prague, Czech Republic) assessing the safety and efficacy of the procedure. METHOD: From April 2008 to March 2010, 25 procedures were performed in 2 reference centers in 25 non-consecutive patients (median age 22 years and median weight 60 kg) under general anesthesia and transesophageal echocardiographic monitoring. Atrial septal defects were single in 23 cases and multiple in 2 cases and had a mean diameter of 17.5 ± 9.4 mm. In one patient it was necessary to use two devices in two distant atrial septal defects. The mean diameter of the devices was 20.8 ± 7.4 mm and they were implanted through 9-14 F long sheaths in the femoral vein. RESULTS: Successful implantation was observed in all cases. In one case, there was embolization immediately after device release. The device was retrieved from the descending aorta followed by implantation of a new device. The mean follow-up was 12 months and the occlusion rate was 100%. There were no late complications. CONCLUSION: In this initial experience, percutaneous occlusion of the atrial septal defect with the Figulla device was easy to perform, safe and highly effective.

INTRODUÇÃO: O tratamento percutâneo da comunicação interventricular (CIV) congênita vem sendo realizado com bons resultados nos últimos 10 anos. Relatamos nossa experiência com a oclusão percutânea da CIV muscular congênita com próteses Amplatzer, avaliando exeqüibilidade, segurança e eficácia do método. MÉTODO: No período de setembro de 2002 a dezembro de 2007, foram realizados 9 procedimentos em múltiplos centros em 8 pacientes não-consecutivos (mediana de idade de 6 anos e de peso de 26 kg), sob anestesia geral e monitoração pela ecocardiografia transesofágica. Todas as CIVs eram únicas (7 na região trabecular média e 1 na porção anterior) e tinham diâmetro médio de 6,0 ± 2,1 mm. Houve embolização imediata de um dispositivo com resgate percutâneo. O procedimento foi repetido com sucesso após um ano. Todos os casos restantes foram realizados com sucesso, sem complicações maiores. O índice de oclusão foi de 100% no seguimento. CONCLUSÃO: Nessa pequena série de pacientes, a oclusão percutânea da CIV muscular congênita única com próteses Amplatzer foi um procedimento de fácil execução, seguro e altamente eficaz.

BACKGROUND: Percutaneous treatment of muscular ventricular septal defects (VSD) has been performed with good results in the last 10 years. We report our experience with the percutaneous closure of congenital muscular VSDs with Amplatzer devices assessing the feasibility, safety and efficacy of the procedure. METHODS: From 9/2002 to 12/ 2007, 9 procedures were performed in multiple centers in 8 non-consecutive patients (median age: 6 years; median weight: 26 kg) under general anesthesia and transesophageal echocardiographic monitoring. All VSDs were single (7 in the trabecular region and 1 anterior) and had a mean diameter of 6.0 ± 2.1 mm. There was one device embolization with immediate percutaneous device retrieval. This procedure was successfully repeated after a year. The other cases were completed successfully without major complications. The rate of complete closure was 100% at follow-up. CONCLUSION: In this small series of patients, percutaneous closure of congenital single muscular VSD was relatively easy to perform, safe and highly effective.

Relatamos um caso de um neonato portador de transposição completa das grandes artérias que foi submetido a atrioseptostomia de Rashkind por acesso trans-hepático por interrupção congênita da veia cava inferior. Os aspectos técnicos do procedimento são discutidos.

We report a case in which a neonate with complete transposition of the great arteries was submitted to an atrial septostomy through transhepatic access due to congenital interruption of the inferior vena cava. The technical aspects of the procedure are discussed.

OBJECTIVE: To report short and midtem follow-up results of balloon aortic valvuloplasty to treat congenital aortic stenosis. METHODS: Seventy-five patients (median age: 8 years) underwent the procedure through the retrograde femoral or carotid route. RESULTS: The procedure was completed in 74 patients (98.6%). The peak-to-peak systolic gradient dropped from 79.6±27.7 to 22.3±17.8 mmHg (P<0.001), the left ventricular systolic pressure dropped from 164±39.1 to 110±24.8 mmHg (P<0.001), and the left ventricular end diastolic pressure dropped from 13.3±5.5 to 8.5±8.3 mmHg (P< 0.01). Four patients (5.3%) died due to the procedure. Aortic regurgitation (AoR) appeared or worsened in 27/71 (38%) patients, and no immediate surgical intervention was required. A mean follow-up of 50±38 months was obtained in 37 patients. Restenosis and significant AoR were observed in 16.6% of the patients. The estimates for being restenosis-free and for having significant AoR in 90 months were 60% and 50%, respectively. CONCLUSION: Aortic valvuloplasty was considered the initial palliative method of choice in managing congenital aortic stenosis, with satisfactory short- and midterm results.

We report a case in which the Amplatzer device for percutaneous occlusion of ductus arteriosus was successfully used for occluding a large systemic-pulmonary collateral vessel in a patient who had previously undergone surgery for correction of pulmonary atresia and ventricular septal defect (Rastelli technique), and was awaiting the change of a cardiac tube. In the first attempt, the device embolized to the distal pulmonary bed and, after being rescued with a Bitome, it was appropriately repositioned with no complications and with total occlusion of the vessel.

OBJECTIVE - To report the results of percutaneous occlusion of persistent ductus arteriosus with the Amplatzer prosthesis in 2 Brazilian cardiological centers. METHODS - From May 1998 to July 2000, 33 patients with clinical and laboratory diagnosis of persistent ductus arteriosus underwent attempts at percutaneous implantation of the Amplatzer prosthesis. The median age was 36 months (from 6 months to 38 years), and the median weight was 14kg (from 6 to 92kg). Sixteen patients (48.5%) were under 2 years of age at the time of the procedure. All patients were followed up with periodical clinical and echocardiographic evaluations to assess the presence and degree of residual shunt and possible complications, such as pseudocoarctation of the aorta and left pulmonary artery stenosis. RESULTS - The minimum diameter of the arterial ducts ranged from 2.5 to 7.0mm (mean of 4.0±1.0, median of 3.9). The rate of success for implantation of the prosthesis was 100%. Femoral pulse was lost in 1 patient. The echocardiogram revealed total closure prior to hospital discharge in 30 patients, and in the follow-up visit 3 months later in the 3 remaining patients. The mean follow-up duration was 6.4±3.4 months. All patients were clinically well, asymptomatic, and did not need medication. No patient had narrowing of the left pulmonary artery or of the aorta. No early or late embolic events occurred, nor did infectious endarteritis. A new hospital admission was not required for any patient. CONCLUSION - The Amplatzer prosthesis for persistent ductus arteriosus is safe and highly effective for occlusion of ductus arteriosus of varied diameters, including large ones in small symptomatic infants.

We report new percutaneous techniques for perforating the pulmonary valve in pulmonary atresia with intact ventricular septum, in 3 newborns who had this birth defect. There was mild to moderate hypoplastic right ventricle, a patent infundibulum, and no coronary-cavitary communications. We succeeded in all cases, and no complications related to the procedure occurred. The new coaxial radiofrequency system was easy to handle, which simplified the procedure. Two patients required an additional source of pulmonary flow (Blalock-Taussig shunt) in the first week after catheterization. All patients had a satisfactory short-term clinical evolution and will undergo recatheterization within 1 year to define the next therapeutic strategy. We conclude that this technique may be safely and efficiently performed, especially when the new coaxial radiofrequency system is used, and it may become the initial treatment of choice in select neonates with pulmonary atresia and intact ventricular septum.

OBJETIVO: Analisar a experiência inicial no fechamento percutâneo da comunicação interatrial ostium secundum (CIA OS) com a prótese de Amplatzer. MÉTODOS: Sete pacientes foram submetidos ao procedimento através da via venosa anterógrada, orientados pela ecocardiografia transesofágica (ETE) e sob anestesia geral. Uma criança era portadora de 2 CIA e de canal arterial (CA). As CIA medidas pelo ETE variaram de 8,7 a 20mm. Um ecocardiograma transtorácico foi realizado na manhã seguinte do procedimento. RESULTADOS: Oito próteses foram implantadas nos 7 pacientes com sucesso. Em um paciente, o CA foi ocluído na mesma sessão com mola de Gianturco, tendo surgido taquicardia supraventricular durante a oclusão de uma das CIA, controlada com adenosina. Todos receberam alta hospitalar na manhã seguinte, com oclusão total dos defeitos. CONCLUSÃO: O procedimento mostrou-se seguro, eficaz e versátil, podendo ser considerado como uma alternativa terapêutica inicial em pacientes selecionados com CIA OS.

PURPOSE: To evaluate our initial experience with percutaneous closure of secundum type atrial septal defects (ASD) with the Amplatzer septal occluder. METHODS: Seven patients underwent occlusion by anterograde approach, under general anesthesia and transesophageal echocardiography (TEE) guidance. One child had 2 ASD and a patent ductus arteriosus (PDA). The ASD size ranged from 8,7 to 20mm as measured by TEE. A transthoracic echocardiogram was performed in the morning after the procedure. RESULTS: Eight devices were successfully implanted in 7 patients and the PDA was occluded with a Gianturco coil at the same session. In this patient, there was an episode of supraventricular tachycardia during the occlusion of one ASD which was reverted with adenosin. All patients were discharged the day after, with complete occlusion of all defects. CONCLUSION: The procedure is safe, effective and versatile. It can be applied as an initial alternative to the treatment of selected patients with ASD.